Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market Share

Statistics for the 2023 & 2024 Acute Bacterial Skin and Skin Structure Infection (ABSSSI) market share, created by Mordor Intelligence™ Industry Reports. Acute Bacterial Skin and Skin Structure Infection (ABSSSI) share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Industry

The acute bacterial skin and skin structure infection market is moderately competitive. The market comprises many small and large market players. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products at lower prices. Some of the market players are Glenmark Pharmaceuticals Ltd, Melinta Therapeutics Inc., Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals Inc., AbbVie Inc. (Allergan PLC), Merck & Co. Inc., Pfizer Inc., Melinta Therapeutics Inc.

Acute Bacterial Skin and Skin Structure Infection Market Leaders

  1. Paratek Pharmaceuticals, Inc.,

  2. Melinta Therapeutics, Inc.,

  3. Merck & Co., Inc.,

  4. Pfizer Inc

  5. AbbVie Inc

*Disclaimer: Major Players sorted in no particular order

absssi.png

Acute Bacterial Skin & Skin Structure Infection Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)